Lapatinib Teva

Lapatinib, the active ingredient in Lapatinib Teva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of HER2‑positive metastatic breast cancer and HER2‑positive gastric cancer in adult patients. GNH USA supplies Lapatinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lapatinib acts on HER2‑driven tumor pathways and is indicated for several HER2‑positive malignancies. - HER2‑positive metastatic breast cancer: improves progression‑free survival when combined with chemotherapy. - HER2‑positive gastric cancer: used in combination regimens to delay disease progression. - HER2‑positive breast cancer (in combination therapy): contributes to tumor control alongside other targeted agents.

Lapatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: watery stools occurring in many patients. - Rash: maculopapular skin eruption, often on trunk. - Nausea: mild to moderate feeling of queasiness. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess baseline health and monitor for specific risks. - Liver function: obtain baseline tests and monitor periodically. - Cardiac status: evaluate ejection fraction prior to treatment and during therapy. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Pregnancy and lactation: avoid use due to unknown fetal risk. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture and light.

Lapatinib interacts with several drug classes that may alter its exposure or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase exposure and risk of adverse events.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours. - Warfarin: monitor INR as lapatinib may affect anticoagulant effect.